RESEARCH TRIANGLE PARK, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics is pleased to announce that its research has been recognized by the 2025 Cellular, Acellular, Matrix-like Products (CAMPs) Summit at its inaugural award ceremony held on February 28, 2025. The awards honor researchers and practitioners who have made significant contributions to CAMPs by producing robust new research data. Merakris Therapeutics’ scientist received the 2025 Best Comparative Trial Award for research on its Dermacyte^® Amniotic Wound Care Matrix. Dermacyte Matrix is used to protect soft tissue defects and chronic, non-healing venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs) and was shown to improve wound closure outcomes in the recognized research. W. Sam Fagg MS PhD received the award from Journal of Wound Care at the CAMPs Summit.

Results from Merakris Therapeutics’ Dermacyte Matrix multicentre clinical trial were recently published in the Journal of Wound Care. The paper, titled “Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study,” demonstrates the efficacy of standalone decellularized human amniotic membrane (DHAM) application to hard-to-heal diabetic foot ulcers and venous leg ulcers.

Key Findings from the Study
The study analyzed 18 wounds in 11 patients. Wounds showed a significant reduction in volume after a single DHAM application, and a 50% reduction in wound size was observed after approximately two DHAM applications.

“Millions of Americans struggle from chronic venous insufficiency (CVI) annually, with up to 3% of adults in the United States developing severe venous leg ulcers (VLUs). Patients often find limited relief from existing treatments, leading to persistent discomfort, heightened infection risk, and diminished well-being,” said W. Sam Fagg MS PhD. “Dermacyte Matrix is a human amniotic membrane allograft developed to revolutionize care for those affected by this challenging condition. We are honored to be recognized by the 2025 CAMPs Summit for our research and development of Dermacyte Matrix.”

About Merakris Therapeutics

Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies.

Merakris Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris’ products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Merakris’ management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole.

PR Contact:
Garth Miller
Nova Marketing Solutions
garth.miller@novamktsolutions.com
919-923-3505